NCCN Guidelines (R) Insights Melanoma, Version 3.2016 Featured Updates to the NCCN Guidelines JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK Coit, D. G., Thompson, J. A., Algazi, A., Andtbacka, R., Bichakjian, C. K., Carson, W. E., Daniels, G. A., Dimaio, D., Fields, R. C., Fleming, M. D., Gastman, B., Gonzalez, R., Guild, V., Johnson, D., Joseph, R. W., Lange, J. R., Martini, M. C., Materin, M. A., Olszanski, A. J., Ott, P., Gupta, A. P., Ross, M. I., Salama, A. K., Skitzki, J., Swetter, S. M., Tanabe, K. K., Torres-Roca, J. F., Trisal, V., Urist, M. M., McMillian, N., Engh, A. 2016; 14 (8): 945-958

Abstract

The NCCN Guidelines for Melanoma have been significantly revised over the past few years in response to emerging data on a number of novel agents and treatment regimens. These NCCN Guidelines Insights summarize the data and rationale supporting extensive changes to the recommendations for systemic therapy in patients with metastatic or unresectable melanoma.

View details for Web of Science ID 000380818400004